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While many folate-receptor (FR) targeting radiotracers have been studied for imaging 
cancers, there is a need for tracers that target inflammation for diagnostic and monitoring 
purposes. Two diseases in which inflammation plays a key role are atherosclerosis and 
myocardial infarction (MI). Inflammation is critical to the development and progression of 
atherosclerosis, which can lead to MI. Higher macrophage levels have been associated with 
adverse remodeling effects in post-MI healing. Given the commonality of these potentially 
fatal conditions, it is of great interest to have a reliable radiotracer available for non-invasive 
detection and monitoring. As FR-β expression is upregulated in active macrophages, it serves 
as a great target for imaging of inflammation. [68Ga]Ga-NOTA-Folate, a new FR-targeting 
radiotracer, was synthesized and biologically evaluated to assess its ability to target 
inflammation in mouse and human atherosclerotic lesions. Mice were studied using in vivo 
positron emission tomography and ex vivo digital autoradiography of aorta sections. Human 
carotid artery tissues were studied in vitro for tracer binding. In addition, rat heart tissue 
sections were incubated in vitro with [68Ga]Ga-NOTA-Folate to evaluate post-MI healing. 
Upon analyzing the in vitro binding, [68Ga]Ga-NOTA-Folate showed significantly higher 
binding in atherosclerotic lesions when compared to tissues treated with folate glucosamine, 
a FR blocker, indicating specificity of [68Ga]Ga-NOTA-Folate via FRs. As the 
atherosclerotic lesions observed in the experimental mice were not so extensive, more in vivo 
studies should be done to verify the results.   
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[18F]FDG  2-Deoxy-2-[18F]-fluoro-D-glucose 
18F   Fluorine-18 
68Ga   Gallium-68 
68Ga-DOTATATE 68Ga-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-
(Tyr3)-octreotate 
Am   Molar activity 
ACE  Angiotensin-converting enzyme 
ApoB100 Apolipoprotein B100 
ARG  Autoradiography 
CHD  Coronary heart disease 
CPS  Counts per second 
CT  Computed tomography 
CVD  Cardiovascular disease 
DOTA  1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
EP-H2O Extra-pure Milli-Q water (182 Ω) 
FR  Folate receptor 
FR+  Folate receptor positive 
FR-α  Folate receptor alpha 
FR-β  Folate receptor beta 
Gy  Gray 
H&E  Hematoxylin and eosin  
HDL  High-density lipoprotein 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid  
HPLC  High-performance liquid chromatography 
iTLC  Instant thin-layer chromatography 
LDL  Low-density lipoproteins 
LDLR  Low-density lipoprotein receptor 
MI  Myocardial infarction 
MR  Magnetic resonance 





PBS  Phosphate-buffered saline 
PET  Positron emission tomography 
PSL  Photostimulated luminescence  
QC  Quality control 
RG  Arginine-glycine-aspartic acid peptide 
ROI  Region of interest 
RT  Room temperature 
SCX  Strong cation exchange 
SPECT Single-photon emission computed tomography 
Sv  Sievert 
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The heartbeat is the first sound of human life. The heart is the first organ we are taught how 
to draw when we are young, albeit not anatomically correct. Among the most fatal diseases 
in developed countries, coronary heart disease (CHD) is consistently the leading cause of 
death, accounting for as much as 23% of all deaths in the United States in 2017 (Murray, 
Phil, and Lopez, 2013; Kochanek et al., 2019). Given the prevalence of these diseases, and 
the vitalness of the integrity of our body’s most precious organ, the need for a less invasive 
and early diagnostic means of monitoring the development or progression of CHD is 
paramount. 
 
Molecular imaging is defined as “the visualization, characterization, and measurement of 
biological processes at the molecular and cellular levels in humans and other living systems” 
(Mankoff, 2007). Using noninvasive molecular imaging allows for a better understanding of 
diseases at the biological level, an understanding that can be used for early detection of 
diseases as well as disease and treatment monitoring. Radiotracers are molecules that contain 
a radionuclide. When used in conjunction with positron emission tomography (PET) 
imaging, radiotracers are used as one of several methods for molecular imaging.  
 
As folate receptors are selectively expressed in active macrophages, [68Ga]Ga-NOTA-Folate 
is explored as a new folate receptor-targeting radiotracer aimed at imaging inflammation 
present in two conditions of CHD: atherosclerosis and myocardial infarction (MI). By using 
in vivo PET/CT imaging and ex vivo and in vitro digital autoradiography, [68Ga]Ga-NOTA-










Since the 1970s, the rate of CHD deaths has seemingly decreased in most developed 
countries such as Japan, the USA, and around western Europe (Levi et al., 2002). As Ford et 
al. have detailed, 44% of the decreases in the USA are due to recognition and interventions 
for reducing risk factors. Such risk factors include smoking, poor dietary choices, physical 
inactivity and high body mass index, cholesterol levels, systolic blood pressure and fasting 
plasma glucose levels (Ford et al., 2007). Additionally, around 47% of the decreases in CHD 
deaths are due to medical treatments, such as acute MI or unstable angina treatments, 
preventative therapies after an initial MI, and treatments for chronic angina (Virani et al., 
2020; Ford et al., 2007).  
 
Despite CHD deaths having steadily decreased, age-adjusted rates of death have shown part 
of the decline is due to these deaths occurring later in life and therefore impact the overall 
life expectancy of various countries (Roger, 2007). Furthermore, CHD remains the leading 
cause of death in developed countries, accounting for just under a quarter of all 2017 deaths 
in the USA (Murray, Phil, and Lopez, 2013; Kochanek et al., 2019).  
 
Atherosclerosis is a highly prevalent cardiovascular disease characterized by plaque buildup 
on artery walls, with disease progression relying on inflammation. Atherosclerosis is the 
gradual disease that begins CHD and often leads to more serious complications, such as 
angina, MI or death. 
 
2.1.1 Disease Progression 
 
Low-density lipoproteins (LDL) normally transport cholesterol and fatty acids to tissues 
around the body. When there is too much LDL in the blood, however, it can oxidize in the 





formation of foam cells, which over time turn to atherosclerotic plaques that can undergo 
fibrosis and calcify (Lu and Daugherty, 2015; Bentzon et al., 2014). This cascade of events 
narrows the artery over time, leading to CHD. 
 
As large amounts of plaque accumulate in the arterial walls, the plaques can rupture or break 
off, creating a clot downstream and stopping blood flow. When a clot restricting blood flow 
occurs in the brain, the patient suffers from a stroke and when it occurs in one of the coronary 
arteries leading to the heart, the patient suffers a myocardial infarction (MI), or heart attack 
(Bentzon et al., 2014).  
 
2.1.2 Risk Factors 
 
While many CHD-related deaths occur later in life, development of atherosclerosis can occur 
at any time, as fatty streaks, the first stage of atherosclerosis formation, have been identified 
in fetal arteries (Napoli et al., 1997). Risk factors can increase the potential for atherosclerotic 
development. Rafieinan-Kopaei et al. have detailed several of the known risk factors of 
atherosclerosis, including high blood cholesterol, smoking, high blood pressure, obesity, 
insulin resistance, diabetes, family history, age, and inflammation (Rafieian-Kopaei et al., 
2014). Having more than one of these factors further increases the chances of atherosclerotic 
plaque development. 
 
Having high cholesterol, particularly LDL cholesterol, increases the chance of oxidation of 
LDL in the bloodstream, which triggers the atherosclerosis development cascade. In addition 
to restricting oxygen to the body, smoking damages blood vessels. Damage to blood vessels 
also occurs with high blood pressure, a condition that has been shown to speed up the 
development of atherosclerosis. When blood vessels are damaged, the body sends signals for 
repair, which causes inflammation, again triggering the cascade (Rafieian-Kopaei et al., 
2014).  
 
In addition to these risk factors, other lifestyle habits that can increase the risk of developing 





worsen many of the other risk factors, such as high blood cholesterol and obesity (Rafieian-
Kopaei et al., 2014). By eating foods high in cholesterol and saturated and trans fats, the risk 
of developing high LDL cholesterol increases. Additionally, consuming foods high in sodium 
can worsen high blood pressure. Changing dietary habits by reducing the consumption of 
these unhealthy foods and having a balanced diet with adequate plant sterol consumption can 
lower LDL cholesterol and raise high-density lipoprotein (HDL) cholesterol, reducing the 
risk of atherosclerosis (Clifton and Keogh, 2018). Furthermore, regular physical activity has 
been proven to positively affect the endothelial function of blood vessels as well as lipid 
metabolism, raising HDL cholesterol levels while lowering triglyceride levels (Al-Mamari, 
2009).  
 
2.1.3 Diagnostic Methods 
 
While reducing manageable risk factors is a great preventative measure and treatment for the 
beginning stages of atherosclerosis, usually the disease has progressed too far at the point of 
diagnosis. Given that atherosclerosis is usually sub-clinical until angina or MI occurs, there 
is a need for more non-invasive diagnostic techniques to detect the disease before it 
progresses further. Current diagnostic methods include biomarker detection, of which high-
sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 serve to give 
prognosis of atherosclerosis by detecting risk factors such as inflammation, at which point 
the disease is already advanced (Shah, 2010). Additionally, there are noninvasive imaging 
techniques using computed tomography (CT), ultrasonography, and PET for diagnosing 
atherosclerosis.  
 
CT angiography helps visualize arteries, with contrast agents aiding the visualization. 
Depending on the pixel density shown from the scan, plaque and calcifications can be 
distinguished from arterial lumen (Achenbach et al., 2004). After attenuation, plaques are 
seen as darker areas while calcifications are seen as brighter areas. While this provides clear 
images of plaques within arterial walls, the radiation exposure from the procedure makes it 
so that usually only patients having exhibited symptoms of atherosclerosis use this method 






Coronary calcium detection uses CT to image the cardiac region. The image is taken between 
heartbeats and calcification present is shown as a defined area in the image with hyper-
attenuation and can be quantified using several methods, one of the most common being the 
Agatston method (Neves, Andrade, and Monção, 2017). Once quantified, a coronary artery 
calcium score is determined, which has been shown to be prognostic of cardiovascular 
incidence risk. Various studies have determined that a coronary artery calcium score of zero 
in patients with no symptoms is associated with low mortality risk in the long run, while 
some have also suggested that an increase in the score may be related to higher risk of a 
cardiovascular event (Neves, Andrade, and Monção, 2017). The latter requires further 
investigation to determine the true clinical value of changing scores. When used in 
symptomatic patients for disease monitoring, a score above zero was associated with 
significant stenosis observed via angiography (Neves, Andrade, and Monção, 2017). 
 
Noninvasive ultrasonography of carotid arteries is also used for detection of atherosclerosis. 
As detailed by de Groot et al., doppler ultrasonography is useful in noninvasively detecting 
stenosis after almost half of the artery area has been compromised. Brightness 
ultrasonography is a newer method that measures the thickness of the carotid artery wall and 
plaque, known as the intima-media thickness, noninvasively. It has been determined that 
having over a certain amount of thickness seen in the patient’s demographic group was 
associated with future cardiovascular events, such as MI or death, therefore having the 
potential of monitoring risk of a cardiovascular event (de Groot et al., 2008). As ultrasound 
waves cannot penetrate too deeply, noninvasive imaging is limited to vessels close to the 
skin’s surface (Ibañez, Badimon, and Garcia, 2009). 
 
Another noninvasive technique of growing interest for imaging atherosclerosis uses PET 
imaging. The advantage of PET imaging is that it shows metabolic activity rather than just 
anatomy, a feature that can be of great use when diagnosing and monitoring atherosclerosis. 
As the field is growing, only a few radiotracers are available for targeting atherosclerotic 
plaques, therefore there is a need for radiotracer development to both metabolically and 








The need for treatment to manage atherosclerosis is paramount, as having the disease go 
unchecked can be fatal. While preventative measures through a healthy lifestyle are ideal, 
there are options available for treating the disease once it has progressed, most of which are 
targeted at managing the risk factors.  
 
As Bergheanu, Bodde, and Jukema describe, statins are the leading drug for treating 
atherosclerosis. Statins are reductase inhibitors that increase expression of LDL receptors 
(LDLR), which take up LDL from the bloodstream. By decreasing LDL, this cam help reduce 
LDL oxidation in the bloodstream, preventing more plaque formation. Cholesterol 
absorption inhibitors also reduce LDL in the blood, as do bile acid sequestrants.  To improve 
blood lipid levels, statins also lower blood triglycerides. Research is also ongoing to 
determine whether omega-3 fatty acids can also reduce blood triglyceride levels. 
Furthermore, HDL can be increased using statins and cholesterol ester transfer protein 
inhibitors (Bergheanu, Bodde, and Jukema, 2017). 
 
As the main goal is to avoid a more serious cardiac event caused by atherosclerosis, research 
is being conducted for disease detection and treatment monitoring. To study the disease, an 
experimental mouse model deficient in low-density lipoprotein receptors and only expressing 
apolipoprotein B100 (LDLR-/-/ApoB100/100) can be used. By lacking LDLRs, LDL is not 
taken up and therefore leads to high LDL cholesterol levels. Apolipoprotein B100 
(ApoB100) is part of LDL and plays a key role in the development of very low density 
lipoproteins (VLDL), thereby regulating lipid metabolism. When studied in mice, the 
combination of LDLR deficiency and the expression of apolipoprotein B100 had high 
cholesterol levels and were noted to have advanced atherosclerotic plaques when fed on low-
fat diets (Véniant, M. M., 1998). By using this strain fed a high-fat diet, the chances of 







2.2 Myocardial Infarction 
 
A serious complication of CHD, MI is most universally defined as prolonged ischemia, or 
lack of oxygen, causing myocyte damage and death. This can be the result of a blood clot in 
a coronary artery of the heart, due to either narrowing of the artery or plaque breakoff, as 
well as an imbalance in oxygen supply and demand, sudden cardiac death, as well as during 
surgical intervention (Thygesen et al., 2007). 
 
2.2.1 Disease Progression 
 
When an artery is blocked, blood flow to the heart is cut off and causes an inhibition of 
nutrients and oxygen to the tissue downstream, known as ischemia, which leads to tissue 
damage. This damage varies depending on the size and location of the clot, though it causes 
myocyte death and a degree of necrosis nonetheless (Curley et al., 2018).  
 
The body immediately signals for an inflammatory response to occur at the site following 
the tissue damage. The inflammation helps repair the tissue immediately after MI, though it 
leads to the eventual development of scar tissue and adverse structural and functional changes 
in the heart. A few of these changes seen include remodeling of the left ventricle to alter its 
shape and function, which can lead to a reduction of contractibility that can most likely cause 
eventual heart failure and death (van der Laan, Nahrendorf, and Piek, 2012).  
 
Macrophages help during various stages of inflammation post-MI. They help in digesting the 
dead cells and any debris around as well as secrete growth factors to promote angiogenesis. 
When thinking of prognosis after MI, macrophage concentration has been shown to be a 
predictor of adverse remodeling effects, with increased adverse effects in function seemingly 
associated with higher concentrations of classical macrophages in the blood (van der Laan, 
Nahrendorf, and Piek, 2012). For this reason, it is of great interest to study a target-specific 
tracer to accurately and non-invasively image the post-MI inflammatory state, as it can help 






2.2.2 Risk Factors 
 
As atherosclerosis is part of the prerequisite of MI, the risk factors associated with 
development of atherosclerosis are the same as for MI, including smoking, diabetes, 
unhealthy blood lipid levels, and hypertension (Rafieian-Kopaei et al., 2014). Acute MI may 
occur for various reasons, however among many cases there are several common triggers, 
such as stressful events, coffee or alcohol consumption, physical exertion and heavy meals 
(Baccarelli and Benjamin, 2013). 
 
2.2.3 Diagnostic Methods 
 
There are several methods for diagnosing MI. Many biomarkers are used for the detection of 
myocardial damage after MI, such as creatine kinase and troponins (Howard-Alpe, Sear and 
Foex, 2006). There are also several imaging techniques used for visualizing MI and its 
healing by using magnetic resonance (MR), PET, CT and single-photon emission computed 
tomography (SPECT). These imaging modalities help visualize the heart’s structure and 
function after MI (Naresh et al., 2012).  
 
Chest X-rays are the most used tool for visualizing any ventricular disfunctions after MI 
(Esmaeilzadeh, Parsaee, and Maleki, 2013; Minicucci et al., 2011). Echocardiograms are 
done using ultrasonography to visualize cardiac function. This can help provide information 
regarding ventricular systolic and diastolic function, which can help diagnose MI 
(Esmaeilzadeh, Parsaee, and Maleki, 2013). 
 
Using various protocols, MR has been used for MI visualization. Depending on the sequence 
done, information such as the morphology of the heart, presence of edema, and regional 
function can be given. This is then useful in determining the severity of the MI, its age, 
complications associated and predicting therapy responses (Rajiah et al., 2013). The images 
produced from MR are of great value and show great contrast, all without radiation exposure. 
While not as popular as MR, MI has also been diagnosed using CT scans, including the use 






Myocardial perfusion imaging using PET can be used to visualize the blood flow of the heart 
after MI. For this, [15O]H2O, [
82Rb]RbCl, and [13N]NH3 are used clinically, with other 
radiotracers being investigated for this purpose (Li et al., 2014). Myocardial metabolism can 
also be imaged using PET in order to see the viability of the myocardium post MI and 
determine eligibility for potential revascularization surgery. The oxygen consumption of the 
heart may be assessed using [15O]O2, while oxygen metabolism may be assessed using 
[11C]acetate (Li et al., 2014). A few other pre-clinical radiotracers have been designed to 




As is the case with atherosclerosis, ideal treatment of MI would be preventative measures 
with a healthy lifestyle to reduce risk factors before MI occurs. This, however, is not the 
reality in most cases and therefore several treatment options are available following MI. 
 
Both immediate and chronic treatments following MI can help reduce the adverse remodeling 
effects to prevent heart failure. As described by Minicucci et al., following MI, diuretics can 
be used to manage excess water and sodium present while also potentially serving as 
vasodilators. Nitrates may also be given to help dilate vessels and help relieve heart failure 
symptoms post-MI. Angiotensin-converting enzyme (ACE) inhibitors also help to dilate 
blood vessels, reducing blood pressure. Surgical intervention may also include installing a 
left ventricular assist device (LVAD), which can aid in pumping the heart (Minicucci et al., 
2011).  
 
In order to help prevent another cardiac event, as well as adverse remodeling effects, several 
drugs may be used chronically that have been proven effective against remodeling. These 
include ACE inhibitors, antiogensin-II receptor blockers, and β-andrenergic blocking agents, 
or β-blockers. Other treatments include stem cell therapy as well as surgically inserting a 






By using molecular imaging, oxygen metabolism as well as potential myocardial viability 
may be observed as responses to treatments and therefore can help give personalized patient 
care to achieve the best outcome possible. As molecular imaging technologies advance, the 
ability to specifically deliver drugs to desired areas can help improve post-MI treatments. 
 
2.3 Imaging Modalities 
2.3.1 Positron Emission Tomography 
PET is a noninvasive imaging technique that requires a radioactively labeled material, known 
as radiotracers or radiopharmaceuticals, to visualize metabolic states. This imaging modality 
is commonly used for molecular imaging, as it is useful for disease monitoring since diseases 
are metabolically active. The lack of anatomical reference, however, requires it be used in 
conjunction with either MR or CT. 
PET scans use radiation in the form of positrons (+), which are produced in the nucleus of 
a nuclide that contains an imbalanced number of protons to neutrons. When this type of 
nuclide decays, the excess proton is released as a positron and a neutrino. The neutrino does 
not interact with its surroundings, but the positron interacts with electrons, causing 
annihilation. With annihilation, the positron and electron become  ray photons and emit 511 
keV of energy each while traveling in opposite directions (Mikla and Mikla, 2014). 
Scintillation detectors, single crystals that deposit  rays and in turn convert them into 







Figure 1. Visualization of annihilation event in PET imaging. An electron (e-) and positron (+) interact 
and convert to photons, emitting 511 keV each as they travel in nearly opposite directions until they hit a 
detector along the ring of detectors. Created on Biorender.com. 
 
As annihilation events send photons in almost opposite directions, the detectors have near-
simultaneous detections after annihilation. When detected at nearly identical times, this is 
known as a coincidence event and the signals are then used to localize the point of 
annihilation. Photomultiplier tubes generate an electrical signal from the photons. This signal 
is then used to detect the point of annihilation using a line of response. Many of these lines 
of responses coming from different directions allow for tomographic acquisition of the 
radioactivity. Algorithms are then used to reconstruct the images and determine which points 
have the highest radioactivity accumulation (Spanoudaki and Levin, 2010). 
Common radionuclides used in PET imaging that emit positrons include 18F, 11C, 64Cu, 89Zr, 





generator, eliminating the need for a cyclotron. This allows for convenient implementation 
in a radiochemistry lab. Additionally, apart from 11C, 68Ga has the shortest half-life at 67.7 
minutes, which decreases the radiation exposure to a patient. Furthermore, 68Ga has an 89% 
positron yield, favorable for PET imaging as more positrons can help provide a clearer image 
(Velikyan, 2018; Silvola et al., 2011). These qualities make 68Ga a favorable radionuclide to 
work with for PET imaging.  
 
When using a radiotracer for PET imaging, molar activity (Am), the amount of radioactivity 
in the amount of radiotracer end product, including non-radioactive biproducts, should be 
high. By increasing the Am, smaller amount in terms of molarity of these radiotracers are 
required; this is particularly of great importance in pre-clinical imaging of small animals, as 
they need higher doses to get enough signal to combat background noise (Sergeev et al., 
2018). 
 
To quantify the activity of a radiotracer to the site of interest in vivo, the highest maximum 
target-to-background ratio (TBR) is used. For measuring activity in plaques within the aortic 
arches, the target is the aortic arch uptake and the background is the blood flow present in 
the aortic arch. The activity within the region of interest, known as standardized uptake value 
(SUV), is used to calculate the highest maximum TBR and is calculated as follows:  
 





When calculating the SUV, the radioactivity concentration refers to the concentration of 
radioactivity within the tissue volume. When working with small animals such as mice, the 
units can be expressed as kBq/mL. This value is then divided by the administered dose of 
decay-corrected radioactivity per weight of the patient. In imaging of small animals, this 
would be expressed as kBq/g, therefore making the units of SUV g/mL. The SUV values are 











Calculating the highest maximum TBR is thought to correct for blood flow uptake within the 
targeted area, therefore serving as a more accurate parameter to determine plaque-specific 
uptake in the aortic arch (Chen and Dilsizian, 2015). 
PET imaging is advantageous for several reasons. As mentioned previously, using PET over 
CT or MR allows for biological and metabolic imaging, a feature that is essential for 
monitoring diseases. When combining PET with CT or MR, the anatomical component can 
be included and therefore the localization of observed metabolic activities can be done. When 
compared to SPECT, both imaging modalities provide 3D metabolic images, which are 
useful for visualization and understanding biological processes. SPECT, however, is 
measured by single gamma photons, where PET is measured by coincident events from the 
photons of annihilation. By using two points to detect the annihilation point, more 
localization information is provided by PET, giving it a higher spatial resolution of 2.5-6 mm 
to that SPECT at 8-15 mm (Livieratos, 2013; Li et al., 2013). PET also has higher sensitivity 
and temporal resolution that SPECT and the radiotracers used in PET, such as 18F or 68Ga at 
less than two hours, have shorter half-lives than those used in SPECT, such as 99mTc at nearly 
five hours, which gives the patient a lower radiation dose (Li et al., 2014). 
The disadvantages of PET imaging include the lack of anatomical reference, however as 
previously mentioned, this can be addressed by combining PET with MR and CT. Another 
disadvantage is the potential time of the scan. While the type of scan and radiotracer used 
changes the time, it can take several minutes in addition to the time waiting for the radiotracer 
to distribute. Additionally, by administering a radiotracer, there is radiation exposure to the 








2.3.2 Computed Tomography 
 
Computed tomography (CT) uses X-rays to non-invasively construct an image that gives 
anatomical information. As PET imaging provides metabolic information, combining CT 
with PET and superimposing the results both scans gives metabolic information with 
anatomical reference in order to know the location form which the information from the PET 
scan is coming from.  
 
The most common CT scanners are helical CT scanners, which acquire their data by rotating 
around the patient while continuously shooting X-ray beams and acquiring the information. 
Hundreds to thousands of detectors are used and work in the same way as those used in PET 
scans. Once the X-ray beam passes through the patient, the detectors, consisting scintillation 
crystals followed by photodiodes, take up the X-ray photon and convert it to an electrical 
signal (Mikla and Mikla, 2014). In order to acquire enough data and keep the patient’s 
radiation dose as low as reasonably achievable, the detectors must be highly efficient, 
detecting at least 80% of the emitted X-rays; with improving efficiency and sensitivity of 
these detectors, scans are completed in the time it takes most patients to hold their breath 
(Overdick, 2006). Upon acquiring data, image reconstruction is done to correct for any 
patient movement as well as X-ray scatter. Iterative reconstruction is done to create the 2D 
or 3D CT scan image from the acquired data. To reduce the overall radiation exposure to 
patients, better reconstructive methods have been developed to correct for problems that arise 
with lower X-ray doses during scans, such as lower signal-to-noise ratios giving noisier 
images (Willemink and Noël, 2019).  
 
When doing a PET/CT scan, the first step includes attenuation correction. Attenuation 
correction allows for changes in intensity due to scatter and absorption to be corrected, 
resulting in a more accurate anatomical image (Mikla and Mikla, 2014). When studied in the 
canine model, Chin et al. determined that attenuation correction was needed to get more 
accurate radiotracer activity measurements, as the respiratory movements misaligned the 
diaphragm and led to inaccurate activity results (Chin et al., 2003). When studied in mice, 





attenuation correction, showing that attenuation correction must also be done in pre-clinical 
animal studies in order to achieve more reliable results (D’Ambriosio et al., 2013).  
 
As previously mentioned, one of the advantages of CT scans is the acquisition of the image 
within the span of one held breath. This rapidness in image acquisition also reduces the time 
of radiation exposure. CT scans also provide 3D images, giving useful anatomical reference 
throughout the scanned area. With a high spatial resolution of 0.5-0.625 mm and a fast 
temporal resolution between 83-135 ms, this imaging modality is advantageous in many 
ways (Lin and Alessio, 2009). 
 
Disadvantages of CT scans include the lower contrast resolution when compared to MR or 
PET (Lin and Alessio, 2009). Additionally, while the high temporal resolution allows for fast 
scans, there is still radiation exposure when using CT imaging, the effects of which are 
detailed below.  
  
2.3.3 Radiation 
Radiation is energy in the form of particles, such as  and  particles, or energy waves, such 
as  or X-rays. Radioactivity is measured in the SI system as Becquerels (Bq; 1 Bq = 1 
disintegration/second). While they have higher ionization potential, the  and  particles do 
not penetrate as deeply through the body as X rays and  rays and therefore can be blocked 
more easily. Paper and skin block  particles and plastic glass and thick aluminum can block 
 particles. By contrast, thick metals like lead or steel can block  and X-rays (Yamamoto, 
2013). 
Some types of radiation can be harmful. The effects caused by harmful radiation can be either 
stochastic or deterministic. As described by Bolus, when exposed to some dose of radiation 
over time, there may be observed side effects.  Common sources of such background 
radiation can be indoor radon gas or soil. Due to the prolonged exposure and low radiation 
level, development of side effects, such as cancer, is random and happens seldomly. These 





during shorter periods of time. Ionizing radiation usually causes these non-stochastic, 
deterministic effects. These effects are known and can be expected after certain levels of 
radiation exposure. Ionizing radiation may affect the cell directly by damaging either proteins 
or DNA with single- or double-strand breaks, or indirectly by hydrolysis of water molecules 
within the cell, yielding free radicals and eventually peroxide hydroxyl molecules, which 
lead to a lack of enzymes in the cell. Both direct and indirect interactions by ionizing 
radiation lead to cell damage and death (Bolus, 2001).  
There are different ways of measuring radiation exposure. As defined by the International 
Commission on Radiological Protection, the first is the absorbed dose, which measures the 
total energy from the radiation and is expressed in gray (Gy). As tissues and their properties 
vary between organs, the second measurement evaluates the radiation dose per tissue or 
organ. This is known as the equivalent dose and is measured in sieverts (Sv; J/kg). The last 
measurement is the effective dose, which adds all the equivalent doses of the different tissues 
or organs and is also expressed as Sv (ICRP, 2007).  
As mentioned previously, there is known radiation exposure with the use of PET/CT 
imaging. When using PET imaging, the radiation is in the form of β+ particles that convert 
to γ photons. This radiation is administered into the body of the subject being imaged. The 
amount of radioactivity from a PET scan varies depending on the radiotracer used and the 
quantity used. In a CT scan, X-rays cause radiation exposure to patients. As is the case with 
PET scans, the radiation exposure of a CT scan varies depending on the type of scan done. 
When measuring various methods of whole-body scanning in patients with 370 MBq 
[18F]FDG, the total effective dose was shown to be between 13.45 and 32.18 mSv, which is 
between five and 13 times higher than the 2.4 mSv calculated annual effective dose from 
background radiation (Huang, Law, and Khong, 2009). In order to make sure the effective 
dose of the scan is as low as possible, the CT image may be limited to a certain area if 
possible, therefore reducing unnecessary exposure. As there is unavoidable radiation 
exposure with PET/CT scans, the risk of this must be outweighed by the potential benefits 








Autoradiography (ARG) is a technique used to localize radionuclides in ex vivo and in vitro 
tissues of interest. Macroautoradiography is done when the tissues of interest have a larger 
area, such as cyosectioned organs on a slide. While there are many ways to do 
autoradiography, the method used in this project included phosphor plates. As detailed by 
Barthe, Maîtrejean and Cardona, these phosphor plates are usually comprised of small 
barium fluorobromide and divalent europium that form a lattice, where spots at which 
bromine is absent serve to trap electrons (Barthe, Maîtrejean and Cardona, 2012).  
 
Once the tissue of interest is radioactive and prepared, either from ex vivo sectioning after 
PET imaging or in vitro incubation in the radiotracer, it is placed in very close proximity to 
the phosphor plate where exposure occurs; the process is shown in Figure 2. During this 
exposure, the radiation from the tissue ionizes the europium, which releases electrons that 
deposit into the bromine vacancies within lattice of the phosphor plate. By excitation with a 
laser beam in a scanner, the electrons are released from the vacancies and upon interacting 
with europium, the europium releases energy in the form of UV photons as it goes back to 
its divalent ground state (Barthe, Maîtrejean and Cardona, 2012). This release of UV photons 







Figure 2. Principle of phosphor screen autoradiography, image is not to scale and has been adapted from 
Barthe, Maîtrejean and Cardona, 2012. (1) Basic phosphor plate lattice with bromine vacancies and 
ground-state divalent europium (Eu+2). (2) Radioactive tissue of interest is placed close to the plate for 
exposure. As exposure occurs, the radiation releases an electron from the europium, becoming Eu+3, and 
the electron fills a bromine vacancy. (3) Upon excitation from a laser in a scanner, electrons filling bromine 
vacancies are released and interact with europium, which goes back to its Eu+2 ground state, releasing 
energy as photons. These photons are captured and converted to electrical signals by the scanner to build 




When developing a radiotracer for molecular imaging, there are several factors to consider, 
as detailed by Chen and Chen. An ideal radiotracer for targeting a molecule should be 
relatively easy to produce in a financially accessible way. It should be able to bind 





quickly to the desired target, thereby increasing the uptake and giving a better signal. 
Additionally, the radiotracer should bind quickly to the target and release slowly afterwards, 
while hardly binding to and having fast clearance from unwanted tissues, giving a high 
contrast ratio that would allow for high signal in desired areas with low background noise. 
The radiotracer should be highly sensitive when binding to desired tissues, reducing the 
amount of radiotracer needed for uptake. Furthermore, the radiotracer should be stable in 
vivo, with no biological factors affecting its structure, as well as have little or no toxicity 
(Chen and Chen, 2010). 
Folate describes folic acid and related compounds with biological activity of folic acid. Folic 
acid is a B-vitamin that is essential in proper cell growth. The primary function of folate 
coenzymes involves 1-carbon reactions, either accepting or donating one carbon in various 
processes, such as: Amino acid metabolism, purine, pyrimidine, and thymidylate synthesis, 
and producing S-Adenosyl methionine, the body’s main methyl donor that is involved in 
DNA methylation and over 100 other metabolic reactions (Doucette and Stevens, 2001).  
After absorption, folic acid is transported mainly as 5-methyl-THF (5-MTHF) bound to 
albumin in the plasma. To enter cells, the monoglutamate form is taken up by one of two 
mechanisms: reduced folate carriers or folate receptors (FR), the latter being expressed only 
in limited tissues, since reduced folate carriers take up necessary folates (Doucette and 
Stevens, 2001). As one of the tissues expressing FRs are active macrophages, this is an 
interesting target for imaging inflammation (Jager et al., 2012). 
To date, a few radiotracers have been developed to target atherosclerotic inflammation using 
PET imaging. The most common clinically used radiopharmaceutical has been 2-deoxy-2-
[18F]fluoro-D-glucose, or [18F]FDG, which gives strong signals from plaques, however it can 
also give unwanted signals from other tissues, as it is not specific to inflammatory tissues. 
Additionally, this can be an inconvenience to patients, as they are asked to fast for long 
periods of time to avoid other unnecessary uptake in muscles and higher-than-normal blood 
glucose ranges that can alter signals (Hyafil and Vigne, 2019).  
 
[68Ga]Ga-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-(Tyr3)-octreotate, or 





macrophages, and has also been studied clinically. It seems to have high specificity for the 
somatostatin receptor 2, which can be useful (Tarkin et al., 2017). Another clinical study 
using [68Ga]Ga-DOTATATE demonstrated the tracer’s ability to be taken up in calcified 
plaques in the left anterior descending coronary artery while having lower myocardial uptake 
than [18F]FDG, giving more clarity of the plaques when imaging (Rominger et al., 2010). An 
additional tracer studied pre-clinically in mice and rabbits is aluminum fluoride-18 labeled 
NOTA-conjugated folate, or 18F-FOL. This tracer targeted FR-β in atherosclerotic lesions 
and seemed to provide high specificity for imaging (Silvola et al., 2018).   
 
Several radiotracers have been developed for imaging of MI, such as [68Ga]Ga-DOTA-E-[c-
(RDGfK)]2 and [
68Ga]Ga-NODAGA-exendin-4. The first uses an RG (arginine-glycine-
aspartic acid) peptide to target integrins present post-MI for evaluating extra-cellular matrix 
changes, while the latter targets expression of glucagon-like peptide-1 receptor (GLP-1R), a 
receptor that has cardioprotective effects when activated, post-MI (Kiugel et al., 2014; Ståhle 
et al., 2018). [68Ga]Ga-DOTATATE has also been shown to target post-MI residual 
inflammation via somatostatin receptors, as mononuclear phagocytes undergo changes after 
this cardiac event that lead to the macrophages remaining long after the scar tissue has been 
formed, which can contribute further to tissue remodeling and heart failure (Tarkin et al., 
2019; Ismahil et al., 2014). While uptake of [68Ga]Ga-DOTATATE in the myocardium did 
not prove to be significant in mice, clinical evidence in humans counters this as the tracer 
identified recent MI inflammation with low myocardial binding as well as old injuries from 
previous cardiac events, though the latter remains histologically unverified (Thackeray et al., 




[68Ga]Ga-1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA)-Folate, hereon referred to as 
[68Ga]Ga-NOTA-Folate, is a radiotracer developed with a 68Ga-labeled NOTA chelate 
attached to folic acid. Being a bifunctional chelating agent, NOTA can both bind to metals, 
such as gallium, while still having a reactive functional group, allowing for binding to other 





can form a thermodynamically and kinetically stable complex with metals, as well as be more 
lipophilic than other similar chelators, such as DOTA (1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid) (Studer and Meares, 1992).  
 
 
Figure 3. [68Ga]Ga-NOTA-Folate structure. 
 
Because of these properties, [68Ga]Ga-NOTA-Folate has been studied in vivo in mice with 
xenografted FR-positive squamous cell carcinoma KB tumor cells, showing uptake in tumor 
cells with significantly lower uptake in the kidneys when compared to 68Ga-DOTA-Folate. 
The NOTA complex was also more biochemically stable than the DOTA complex. When 
folic acid was added to block the FRs prior to tracer injection, the tumor uptake was 
significantly reduced by about 85%, showing the receptor-specificity of the tracer (Aljammaz 
et al., 2014). When compared to [99mTc]EC20, another FR-targeting imaging agent, 
[68Ga]Ga-NOTA-Folate was shown to have similar tumor uptake levels with significantly 
lower liver uptake and blood activity levels, proving to have better biodistribution in vivo 
(Brand et al., 2017). 
 
While these studies have shown [68Ga]Ga-NOTA-Folate to be a suitable tracer for tumor 
detection, there is a lack of research done to assess the tracer’s ability to target FR-βs and 
image other inflammatory diseases. Given the tracer’s success with targeting the FRs in 
tumor cells, it is of high interest to see whether this same specific targeting can apply to FR-
βs present in active macrophages for detecting and imaging inflammation. While many 
diseases cause inflammation, the two disease models studied will be atherosclerosis in mouse 






2.7 Radiochemistry Analysis Methods 
 
Radiochemical purity is the level of which the end product synthesized is indeed what it is 
supposed to be, compared to other biproducts or impurities that may have been made in the 
synthesis process.  
 
2.7.1 High Performance Liquid Chromatography 
 
Analytical high performance liquid chromatography (HPLC) is a method used for quality 
control analysis, as it distinguishes a chemical’s physical and structural properties (Crowley, 
2020). HPLC requires a column through which solvents and the chemical of interest, or 
analyte, pass. When using reversed-phase HPLC, the column’s stationary phase, comprised 
of unbranched alkanes, is nonpolar and the solvent passed through, or its mobile phase, is 
polar (Bélanger, Paré and Sigouin, 1997).  
 
Separation can occur based on several factors, such as the size, charge and polarity of the 
chemical being observed in addition to the viscosity of the solvent used (Bélanger, Paré and 
Sigouin, 1997). The solvents and columns used should be specific to do the appropriate 
separation for chemical identification. The column used for QC in this project was a Jupiter 
Proteo C18 column, with the particle sizes of 5, 5, 10 and 15 m, and pore size of 300 Å. 
Being a C18 column, the alkanes in the stationary phase are 18 carbons long and are linked 
to spherical silica particles of the sizes listed above. Additionally, the pore size of 300 Å 
refers to the pores within the silica particles. This size is designed to help separate larger 
molecules. The solvents were used in a gradient fashion, changing the amounts used as the 
QC was being done. The mobile phase solvents included hydrophilic water with 0.1% TFA 
and hydrophobic pure acetonitrile. The TFA buffer is added to the water to fully protonate 
any acidic analyte, as full protonation increases molecule stability (Crowley, 2020).  
 
The pump in the HPLC system pumps the solvents through the column, creating pressure 
that pushes the analytes through the column. As the column is hydrophobic, analytes that are 





slower than more hydrophilic and polar analytes. This in turn separates the analytes. The 
retention time of an analyte, or the time it takes to pass through the column, is measured and 
varies depending on its size and polarity, with smaller molecules traveling faster through the 
column than larger ones (Crowley, 2020).  
 
Data from HPLC is given as a chromatogram where the x-axis is the time of the QC run and 
the y-axis is the radioactivity detected in counts per second (CPS). As a compound is pushed 
through the column, its radioactivity will be measured, as will its retention time within the 
column. This produces a peak in the graph. The purity of [68Ga]Ga-NOTA-Folate may be 
assessed using HPLC, as any impurities in the form of free 68Ga being smaller and highly 
polar travel faster through the column and therefore produce its own peak. Being highly 
sensitive and able to give QC results within a few minutes, HPLC is an efficient and reliable 
method to assure radiochemical purity. 
 
2.7.2 Instant Thin Later Chromatography 
 
Instant thin layer chromatography-silica gel (iTLC) is one of the techniques used to quickly 
evaluate the radiochemical purity of a radiopharmaceutical. The iTLC plate can be made of 
a few components, including glass or aluminum foil. For iTLC, there is a stationary phase, a 
mobile phase, and a solute. The iTLC strips used in this project were made from paper coated 
with silica gel, making this adsorbent compound the stationary phase. Other examples of 
materials for stationary phase include cellulose or aluminum oxide. The mobile phase is the 








Figure 4. Visualization of compound separation on iTLC strip. The solute is placed as a small dot on the 
line drawn. The strip is placed in the development chamber, where the developer is pooled below the line 
containing the solute. As the developer moves up the strip’s capillary network, the components within the 
solute are separated based on various properties depending on the conditions used. In this example, the 
strip has silica gel coating and the developer is a slightly acidic buffer. As the buffer travels up the network, 
the most polar substance binds first to the silica in the coating, therefore traveling to the solvent front, 
shown as the black line at the top of the strip, first. The less polar compound remains at the bottom of the 
strip, as most of the silica gel has already been bound. Created on Biorender.com. 
 
When doing iTLC, a small amount of the solute is placed on a small pencil marking made 
on the strip, then the strip is placed into the development chamber, which has the solvent 
pooled at the bottom at a level lower than the solute. The solvent front, a line drawn in marker 
drawn towards the top of the strip, marks the endpoint of the separation. As it is drawn in 
ink, it leaves a bleeding trail as it travels up the strip via the developer. The strip’s stationary 
phase has a capillary network which allows for the solute and mobile phase to compete for 
binding to the stationary phase, going up the strip and separating by different properties in 
the process, as visualized above in Figure 4. One such property is polarity. As silica gel is 





traveling fastest up the strip. By interacting first with the stationary phase, substances with 
higher polarity leave less polar substances to interact with the stationary phase, therefore they 
do not travel as high. Differing substance properties, such as size, polarity, lipophilicity and 
charge, separate at different rates and can be identified (Bele and Khale, 2011; Decristoforo 
et al., 2007).  
 
iTLC is useful for assessing radiochemical purity in an end product, as it can quickly separate 
the impurities from the desired product based on differing properties. The process can be 
done relatively quickly, and as time is critical when working with radionuclides, it serves as 





3 AIMS AND HYPOTHESES 
 
The first aim of this project was to synthesize [68Ga]Ga-NOTA-Folate with high purity, yield, 
and molar activity. When done properly adhering to the protocol, it was hypothesized that 
the end product would be made meeting the aimed criteria.  
 
The second aim of this project was to biologically evaluate [68Ga]Ga-NOTA-Folate in 
atherosclerosis and MI disease models. The atherosclerotic model was assessed using in vivo 
PET/CT imaging with the atherosclerotic mouse model on a high-fat diet and control mouse 
model fed regular chow. Then, tissue sections from mouse aortas were used to evaluate the 
ex vivo binding ability of the tracer to the atherosclerotic lesions present. Upon analyzing, it 
was hypothesized that radioactivity should be present in high concentrations in the 
atherosclerotic lesions co-localizing with FR--positive macrophages. Additionally, 
[68Ga]Ga-NOTA-Folate was used to analyze in vitro binding to atherosclerotic plaques in 
human carotid artery tissue sections using total and blocked tracer binding techniques. It was 
hypothesized that the total binding tissues will have high radioactivity in the atherosclerotic 
lesions, while the blocked binding tissues will have little to no radioactivity. 
 
To biologically evaluate specific binding of [68Ga]Ga-NOTA-Folate to FRs in the MI model, 
heart tissues from rats that had undergone surgically-induced MI operation were used for in 
vitro imaging using the autoradiography technique, or ARG. Half of the tissues were 
incubated with the tracer alone, while half were incubated with FR-specific folate 
glucosamine as a blocker.  It was hypothesized that this tracer will show high radioactivity 
in the areas containing inflammation lesions with high specificity in the tissues with total 
tracer binding, and little to no radioactivity in inflammation lesions in the tissues having been 





4 METHODS AND MATERIALS  
 
4.1 Radiosynthesis of [68Ga]Ga-NOTA-Folate 
 
This radiosynthesis protocol was done six times, with the first being used as a test for 
metabolite analysis, the next four being used for a total of two injections for in vivo imaging 
in mice each, and the final being used for in vitro binding of the tracer to rat MI tissues. The 
generator scheme for the syntheses is detailed in Figure 5.  
 
 
Figure 5. Generator scheme for radiosynthesis of [68Ga]Ga-NOTA-Folate used in in vivo and in vitro 
experiments. Created on Biorender.com. 
 
For in vivo studies with two mice being imaged one hour apart, the ordered amount of 





desirable concentration of 330 MBq/mL. Within 24 hours prior to the radiosynthesis, the 
gallium generator (IGG1000; Eckert & Ziegler, Berlin, Germany) was eluted with 10 mL of 
0.1 M HCl in order to remove any potentially accumulated metal impurities. Once this was 
completed, the radiosynthesis procedure began by combining in the reaction vial 60 mg of 
HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; Merck, Darmstadt, 
Germany) with 50 µL of TraceSELECT water (Honeywell, Bucharest, Romania), 10 µL of 
0.1 M gentisic acid (2,5-dihydroxybenzoic acid; Sigma-Aldrich, Darmstadt, Germany), 
prepared by diluting 10 mg of gentisic acid in 650 µL of TraceSELECT water then vortexed 
until dissolved, and stock solution 20 µL (0.5 nmol/L) of NOTA-Folate precursor (a gift 
from Professor Philip Low, Purdue University, USA) for total a precursor amount of 10 nmol. 
Then 6 mL of 0.1 M HCl were eluted through the generator at a rate of about 2 mL per 
minute, stopping briefly halfway to collect a 0.6 mL fraction after about 2.4 mL have been 
eluted. From the fraction collected, 0.5 mL was then transferred to the reaction vial and 
vortexed before 10 minutes of incubation at 80° C. After incubation, the reaction vial was 
cooled in ice for 2 minutes and 55 µL of 1 M NaOH are added to raise the pH to around 5-7. 
The final radioactivity was measured, and a diluted sample of the product was used for high-
performance liquid chromatography (HPLC) quality control (QC) analysis. As the QC was 
done, the final [68Ga]Ga-NOTA-Folate product was sent for delivery to BioCity. Upon 
completion of a successful QC, the product could then be injected into the mice. 
 
The QC was done using analytical HPLC with a Jupiter Proteo C18 column, 5 m 300 Å 150 
× 4.6 mm and UV set to 254 nm. Solvent A was Milli-Q water (182 Ω) with 0.1% 
trifluoroacetic acid (TFA; Merck, Darmstadt, Germany) and solvent B was acetonitrile with 
0.1% TFA. The method used was 68Ga-NOTA-Folate QC and is as follows:  
 
Time Point Solvent A (%) Solvent B (%) Flow Rate 
0 minutes 97 3 1 mL/minute 
14 minutes 65 35 1 mL/minute 
14.1 minutes 68 32 1 mL/minute 





14.3 minutes 74 26 1 mL/minute 
14.4 minutes 77 23 1 mL/minute 
14.5 minutes 80 20 1 mL/minute 
15 minutes 97 3 1 mL/minute 
 
4.2 Optimization of Concentrated [68Ga]Ga-NOTA-Folate Radiosynthesis 
Procedure 
 
The protocol for the radiosynthesis of concentrated [68Ga]Ga-NOTA-Folate using an SCX 
cartridge was tested for optimal NOTA-Folate precursor concentration level. The generator 
scheme is detailed in Figure 6. 
 
Figure 6. Generator scheme for concentrated [68Ga]Ga-NOTA-Folate production using SCX column. 






The initial protocol began with combining 66 mg of HEPES with 10 L of 0.1 M gentisic 
acid, prepared as described previously, and the desired amount of 0.5 nmol/L NOTA-Folate 
precursor and water added to total a volume of 50 L in the reaction vial. Once this was 
prepared, 7 mL of 0.1 M HCl solution was eluted at a rate of 2 mL/min through the gallium 
generator and into waste, passing through a Strata strong cation exchange (SCX) column 
(Phenomenex, Torrance, CA, USA) in the process. The column was then moved to an empty 
vial and 600 L of a 0.1 M HCl/1.0 M NaCl solution were slowly eluted through via the 
cartridge line at a rate of around 2 mL/min. Then, 550 L of this free Gallium solution was 
added to the reaction vial and vortexed. Incubation occurred for 10 minutes at 40° C and 30 
L of 1.0 M NaOH was added at the end of the reaction to increase the pH level. The total 
radioactivity was measured and iTLC (Agilent, Santa Clara, CA, USA) was used to 
determine end product purity.  
 
The different NOTA-Folate precursor concentrations were tested three times for each 
concentration; 10 nmol, 7 nmol, and 5 nmol of NOTA-folate. The amount of precursor added 
to the reaction vial was calculated accordingly per the stock precursor’s 0.5 nmol/L 
concentration, with TraceSELECT water being added to top up the 50 L volume in the 
reaction vial. At the end of each synthesis, a small 1 L portion of the end product was diluted 
in 100 L of TraceSELECT water and 1 L from this dilution was placed on three pre-cut 
iTLC strips. Each strip was then developed in 50 nM of citric acid (C6H8O7) solution and 
upon reaching the marked top line, one of the strips was cut in half and measured separately 
for purity using the gamma counter (1480 Wizard 3”; Perkin Elmer/Wallac, Turku, Finland). 
The remaining two iTLC strips, along with another pre-cut iTLC strip, were used to visualize 
the QC using ARG. While two strips contained the diluted end product, one of those strips 
and the third strip each contained a small 1 L portion of the free gallium solution previously 
collected, diluted in water at a level of 1:200. After development in citric acid, the strips were 
dried with a hairdryer and placed in a plastic bag before being placed in an exposure cassette 
for one hour. After this was done, the ARG imaging plate was scanned, as detailed in the Ex 






4.3 In Vivo PET/CT Imaging  
 
Four 6-month-old low-density lipoprotein receptor deficient male mice only expressing 
apolipoprotein B100 (LDLR-/-/ApoB100/100) on high-fat diet were used as an atherosclerotic 
model and four 3-month-old C57BL/6N strain healthy male mice on regular feed were used 
as controls. Imaging was done using Molecubes X-CUBE and β-CUBE (Molecubes, Gent, 
Belgium). They were anaesthetized with isofluorane (Zoetis Finland Oy, Helsinki, Finland) 
via inhalation with an induction rate of 4-5% at an air flow of 400-500 mL/min, then 
maintained with 1.5-3% at a rate of 150-250 mL/min and injected via tail vein cannula with 
100 µL of eXIA 160 XL contrast agent (Binitio Biomedical, Inc., Ottawa, Canada). They 
were then injected with 40-100µL of [68Ga]Ga-NOTA-Folate (11.8 ± 0.7 MBq; 0.345 ± 0.05 
MBq/kg i.v.). The mice were imaged individually first with the X-CUBE for CT imaging, 
then the β-CUBE for 40 minutes of dynamic PET and high-resolution CT imaging. The mice 
were then sacrificed at 60 minutes post-injection and their organs were collected and weighed 
in pre-weighed tubes, as well as measured using a gamma counter. The aortas were taken to 
the Histocore facility in Medisiina D, where they were sliced for tissue staining and 
autoradiography analysis. 
 
4.4 Ex Vivo Tissue Imaging  
 
The aortas were taken directly to the Histocore after imaging, where they were sliced into 20 
µm and 8 µm sections. The slides containing the tissues were placed on an erased imaging 
plate (Fujifilm, Tokyo, Japan) and left for two hours of exposure time. Once this was 
completed, the imaging plates were scanned using the Fuji Film BAS-5000 scanner (Fuji 
Tokyo, Japan; internal resolution of 25 µm) and saved as digital images in .inf and .img 
formats.  Following this, the 20 µm slides were frozen until they were taken for H&E staining 
at the Histocore. Once the tissues were stained, they were scanned using the Pannoramic 
1000 scanner (3DHistec Ltd., Budapest, Hungary) and saved as digital images. Using the 
ARG and H&E images, analysis was done using Pannoramic Viewer, GIMP 2.0 and TINA 






4.5 Metabolite Analysis In Vitro  
 
The first metabolite analysis was done in vitro on frozen plasma taken previously from a rat 
to verify the protocol method with precipitation and HPLC analysis. The sample was 
defrosted overnight in a 4° C refrigerator, then 1 mL was incubated at 37° C for five minutes. 
After this, 2.04 MBq of [68Ga]Ga-NOTA-Folate was added to the plasma and vortexed. The 
plasma was then incubated once more at 37° C with 200 µL samples being taken at each of 
the following time points: 10, 20, 40, and 60 minutes. Once a sample was taken at a certain 
time point, it was placed in ice to cool, then 200 µL of acetonitrile was added before being 
vortexed then centrifuged at 4500 rpm for 3 minutes. The supernatant liquid was then 
separated into a new Eppendorf tube that was previously weighed. The supernatant sample 
was then weighed and 250 µL was then filtered through a 0.45 µm Minispike filter (Waters 
Corporation, Milford, MA, USA). This filtration was done to avoid any large molecules in 
the plasma from going into the HPLC column. The remainder of the unfiltered supernatant 
liquid was then diluted with 1 mL of 0.1% TFA and 1 mL of this, with a CPS value of 400, 
was used in HPLC metabolite analysis, detailed below. The remaining diluted liquid was 
then weighed and analyzed along with the leftover pellet using a calibrated gamma counter 
(1480 Wizard 3”; Perkin Elmer/Wallac, Turku, Finland).   
 
The QC was done using analytical HPLC column as described in section 3.1 and/or with a 
semi-preparative C18 Jupiter column (250 × 10 mm, Phenomenex Inc., Torrance, CA, USA), 
with a rate of 5 mL/min, UV of 254 nm and radioactivity detection. Solvent A was Milli-Q 
water (180 Ω) with 0.1% TFA and solvent B was acetonitrile with 0.1% TFA. The method 
used was 68Ga-NOTA-Folate-Metab-MGM and was as follows: 
 
Time Point Solvent A (%) Solvent B (%) Flow Rate 
0 minutes 95 5 5 mL/minute 
15 minutes 75 25 5 mL/minute 







4.6 Metabolite Analysis In Vivo 
 
In total, 11 metabolite analyses were done following the in vivo protocol. For the first two 
analyses, two tracer standard methods were done to determine the best one for future use. 
The first one done used 500 µL of previously frozen rat plasma. To this plasma, 500 µL of 
acetonitrile were added to precipitate the proteins. This combination was then vortexed and 
centrifuged at the same rate as detailed above, with the supernatant liquid then being 
transferred to a new Eppendorf tube.  
 
The first tracer standard solution was made in a new Eppendorf tube with a few µL of 
[68Ga]Ga-NOTA-Folate totaling 383 CPS, measured with a well counter, to which 200 µL 
of the supernatant liquid was added. Then, 850 µL of 0.1% TFA solution was added and the 
tube was vortexed. The 1 mL HPLC loop was washed with 2 mL of HPLC-grade pure 
acetonitrile (Merck, Garmstadt, Germany), then 2 mL of 0.1% TFA in water prior to the 
injection of 1 mL of the tracer standard solution. The HPLC analysis was done using the 
same settings as previously mentioned for the in vitro metabolite analysis.  
 
The second tracer standard was done by combining a few µL of [68Ga]Ga-NOTA-Folate 
totaling 405 CPS with 100 µL of acetonitrile and 900 µL of 0.1% TFA. Once combined, the 
solution was vortexed and 1 mL was injected into the HPLC for analysis after washing the 
loop with acetonitrile then 0.1% TFA as described previously. Following the comparison of 
HPLC results between the tracer standards, it was determined that the second method with 
only acetonitrile and TFA would be used as the tracer standard in the remaining analyses. 
 
Following the analysis of the tracer standard with each radiosynthesis of [68Ga]Ga-NOTA-
Folate, another nine metabolite analyses were done in plasma collected after one hour of PET 
imaging of eight atherosclerotic mice with injected [68Ga]Ga-NOTA-Folate. Upon collecting 
blood samples from the mice at 60 minutes post-injection, the plasma was separated through 
centrifugation at the same settings as previously described, then separated into a new tube.  
An equivalent amount of acetonitrile was added to the same tube to separate the proteins in 
the plasma. The plasma was then centrifuged twice with the same setting as previously 





supernatant liquid was then separated into a pre-weighed Eppendorf tube and then weighed 
once more. Then, several µL of the supernatant were transferred to a new Eppendorf tube 
and measured in a well-gamma counter so that the total CPS was between 350-400 CPS, with 
a maximum limit of 200 µL. 0.1% TFA was then added and the tube was vortexed before 
being filtered using a 0.45 µm filter. Once the HPLC column was washed as previously 
described, 1 mL of the filtered sample was injected and analyzed using the HPLC protocol 
for metabolites. The leftover supernatant liquid was then weighed once more before being 
analyzed using the Wizard gamma counter alongside the corresponding pellet.  
 
To ensure the difference in the metabolite and tracer peaks given their close proximity, one 
analysis was done using the supernatant sample from one mouse. The sample was prepared 
as described above, though an additional few µLs of the [68Ga]Ga-NOTA-Folate were added 
before the filtration. One mL of this mixture was then injected into the HPLC and analyzed 
as detailed above in order to see if the metabolite peaks would change. This allowed for 
positive confirmation of the observed metabolite, as discussed under Results.    
 
After completion of the analyses, the HPLC column was cleaned with 50% pure acetonitrile 
and 50% pure Milli-Q water at a rate of 5 mL/minute for 5 minutes, then 70% pure 
acetonitrile and 30% pure Milli-Q water at the same flow rate for 5 minutes. Once this was 
done, the column was stored until the next use.  
 
4.7 In Vitro Blocked Binding Experiment In Human Carotid Arteries 
 
Human carotid artery samples were used to assess the specificity of [68Ga]Ga-NOTA-Folate 
to bind to FRs by in vitro blocking experiments. In total, two experiments were done, both 
following the same protocols with only a slight difference in the amount of radioactivity 
used. The cryosectioned tissues were first defrosted and pre-incubated in PBS buffer for 40 
minutes. As this occurred, the radiosynthesis and QC testing of [68Ga]Ga-NOTA-Folate was 
done as described in the Radiosynthesis of [68Ga]Ga-NOTA-Folate section.  
 
The tissues were then divided into two groups, one that was incubated in PBS with 0.2 MBq 





[68Ga]Ga-NOTA-Folate along with FR blocker folate glucosamine (MW 602 g) at a 
concentration 300 times higher than that of the tracer. Incubation was done in room 
temperature for 45 minutes. After this, the tissues were washed with cold PBS buffer twice, 
then twice again with extra-pure water. They were then dried, using a hairdryer to hasten the 
process, before being placed in a Fijifilm exposure cassette for 2.5 hours for ARG imaging. 
Upon completion of exposure, the imaging plate from inside the cassette was then scanned 
with the BAS-5000 scanner in the same manner previously described.  
 
4.8 In Vitro Blocked Binding Experiment Rat MI Healing 
 
To evaluate the ability of [68Ga]Ga-NOTA-Folate to target inflammation corresponding to 
MI healing, frozen tissue sections from the hearts of rats having undergone an MI-inducing 
operation 3 days prior to euthanasia were provided by a colleague for one in vitro blocked 
binding experiment.  
 
After taking the tissues from the freezer to defrost, they were incubated in PBS solution for 
40 minutes. In the same manner as the previous section, the radiosynthesis and QC testing of 
[68Ga]Ga-NOTA-Folate was done. The successful final product yielded 296 MBq, with an 
activity concentration of 466.7 MBq/mL and a specific activity of 29.64 GBq/µmol. Using 
previous in vitro studies as a reference, 0.9 MBq of the tracer was diluted in 50 mL of PBS. 
This solution was then split evenly into two 25 mL portions, each one with 0.45 MBq. From 
this value, the concentration of the tracer was determined to be 0.015 nmol per portion. Using 
this information, the folate glucosamine blocker was then made into solution with a 
concentration 500 times higher than that of the tracer. From this blocker solution, 37.5 µL 
were added to one portion of the PBS/tracer solution. Accordingly, 37.5 µL of PBS were 
added to the other portion to maintain the same volumes in both. The slides with tissues were 
put into two separate incubation boxes and covered with 16 mL each of their corresponding 
solution, one being designated for total tracer binding with no blocker added and the other 
with the solution containing the blocker. The tissues were incubated here for 45 minutes 
before being washed twice with cold PBS and extra-pure water. They were then dried and 
placed in an exposure cassette for ARG imaging. Following the 2.5 hour exposure, the 






4.9 Image Analysis  
 
The in vivo PET images were analyzed using Carimas 2.10 software (Turku PET Center, 
Finland, www.turkupetcentre.fi/carimas/). The CT image served as anatomical reference in 
order to properly identify the regions of interest, which were the aortic arch and the vena 
cava, which served as an indicator of radioactivity in the blood. Once this was defined for 
every plane applicable, the maximum Bq/mL levels were calculated for the aortic arch. These 
values, along with those of the mean Bq/mL from the vena cava, were then converted to 
kBq/mL which then were used to calculate the SUV and the percent of injected radioactivity 
dose per mL of blood (%ID/mL) values for each animal. The SUV and %ID/mL for the final 
five time points of imaging, 600-2400 seconds, were averaged. From these averages, the 
highest maximum TBR was calculated. The TBR was then used to compare the experimental 
and control groups for differences in uptake in the aortic arch using an independent samples 
t-test. 
 
In vitro and ex vivo images were analyzed using Pannoramic Viewer (3DHistec Ltd., 
Budapest, Hungary), GIMP 2.0 (www.gimp.org), and TINA (Ravtest Isotopemessgeräte, 
GmbH, Straubenhardt, Germany) softwares. The first step in analyzing the images was 
opening the H&E-stained scanned image on Pannoramic Viewer and exporting it as a TIFF 
file with a magnification setting of 1:64 to preserve the data and be able to zoom in for details 
later. Once it was exported and saved, the corresponding ARG image for the slide was opened 
and selected using TINA and exported as a TIFF file as well as saved as a PCBAS file to 
extract the image later. Once both the H&E and ARG images were saved, the H&E image 
was opened on GIMP 2.0 where it was then edited so that the aortas were contoured using 
the lasso selection tool. This was done to have the anatomical reference for the ARG images 
in order to properly identify regions of interest (ROIs) for analysis.  
 
ROIs for mouse tissues, shown in Figure 7, included plaque in the aortic arch (pk), plaque in 
the brachiocephalic artery (pb), plaque in the carotid artery (pc), plaque in the subclavician 
artery (ps), plaque in the descending aorta (pl), healthy vessel wall (w), calcification (c), and 





vessel wall (w). The ROIs for MI rat tissues, shown in Figure 8 included MI scar tissue (s) 
and healthy remote tissue (rem). 
 
 
Figure 7. H&E stained aorta section from an atherosclerotic mouse with labeled ROIs: (1) adventitia; (2) 
wall; (3) plaque in aortic arch (pk); (4) plaque in the brachiocephalic artery (pb); (5) plaque in the carotid 








































Figure 8. H&E stained rat heart 3 days after MI-inducing surgery with labeled ROIs: (1) MI scar tissue 
and (2) remote healthy tissue.  
 
Once the H&E stained image had the aortas outlined with a contour, the contour was 
superimposed onto the ARG image, giving it an anatomical reference. This contoured image 
was then opened on TINA, where the ROIs would be drawn as closely as possible to the 
corresponding areas, which were seen at the same time in the magnified H&E image using 
Pannoramic Viewer. After drawing all ROIs, the data was then exported and statistically 
analyzed. The units used for expressing uptake of [68Ga]Ga-NOTA-Folate were 
photostimulated luminescence per square millimeter, or PSL/mm2. 
 
4.10 Experimental Animals  
 
As an atherosclerotic model, four 6-month-old low-density lipoprotein deficient mice 
expressing only apolipoprotein B100 (LDLR-/-/ApoB100/100) were used (strain #003000, The 
Jackson Laboratory, Bay Harbor, ME, USA). These animals were fed a high-fat diet (0.2% 











four months prior to imaging. Four 3-month-old healthy C57BL/6N mice fed with regular 
chow were used as controls. Four male Sprague-Dawley rats (Central Animal Laboratory, 
University of Turku, Turku, Finland) were used as the MI model.  
 
All animals were housed under standard conditions in an animal facility, with unrestricted 
food and water access and 12 hour light cycles with lights on from 6:00 a.m. to 6:00 p.m. All 
experiments were approved by the Animal Experiment Board in Finland, in addition to the 
Regional state Administrative Agency for Southern or Eastern Finland. The experiments 
were carried out according to the European Union directive. 
 
4.11 Statistical Analyses  
 
Values have been represented as mean ± SD with two significant figures. Two-tailed 
independent samples t-tests were used to compare the highest maximum TBR in the aortic 
arch of atherosclerotic mice and control mice in vivo. Two-tailed independent samples t-tests 
were also used to compare the uptake of [68Ga]Ga-NOTA-Folate between atherosclerotic 
mice and control mice ex vivo in various organs, measured using a gamma counter, 120 
minutes post-injection. Paired t-tests were used to compare the in vitro uptake between 
different tissues from the same subjects on the same ARG imaging plates, with P values of 









5.1 Radiosynthesis of [68Ga]Ga-NOTA-Folate. 
 
The radiosynthesis of [68Ga]Ga-NOTA-Folate for in vivo imaging was successful, as 
determined by the QC using the HPLC protocol detailed earlier. The results yielded a clear 
solution with no particles and a radiochemical purity of 99.4 ± 0.56% (n=4). As two mice 
would be imaged one hour apart for every batch produced, and the maximum radioactivity 
for the imaging camera was 13 MBq, the product decay was calculated from the end of 
synthesis to the estimated injection time approximately 10 minutes after. Taking into account 
the decay and the maximum injection volume being 100 µL for each mouse, the ordered 
amount for each batch at the end of synthesis was calculated to be 520 MBq/mL, with the 
desired radioactivity concentration being determined by the last mouse imaged as 330 
MBq/mL. The average radioactivity was 328 ± 29 MBq and the radioactivity concentration 
was 517 ± 45 MBq/mL, adhering closely to the calculated desired amounts. Additionally, the 
molar activity of 16 ± 1.4 GBq/µmol.  
 
 
Desired Actual (n = 4) 
Radiochemical Purity 95% 99.4 ± 0.56% 
Radioactivity 
Concentration 
520 MBq/mL 517 ± 45 MBq/mL 
Molar Activity (Am) As high as possible 16 ± 1.4 GBq/µL 
Table 1. [68Ga]Ga-NOTA-Folate radiosynthesis results. 
 
5.2 Optimization of Concentrated [68Ga]Ga-NOTA-Folate Radiosynthesis 
Procedure. 
 
After testing NOTA-Folate precursor concentrations of 10 nmol, 7 nmol, and 5 nmol, the 
highest product purity was determined using iTLC and showed that using 10 nmol of 
precursor yielded 99  0.26% purity (n=6) the purity. Using 7 nmol of precursor also 





of precursor, the average purity was below the desired amount with 92  1.9% (n=3) purity. 
When visualizing the QC using iTLC and ARG of [68Ga]Ga-NOTA-Folate, free 68Ga, and 
both applied to the same strip, the pure [68Ga]Ga-NOTA-Folate remained at the bottom of 
the strip while the free 68Ga, having bound to the citric acid developer and becoming 68Ga-
Citrate, was seen at the top of the strip. 
 
NOTA-Folate Precursor Concentration  Radiochemical Purity 
5 nmol* 92  1.9% 
7 nmol* 98  1.4% 
10 nmol† 99  0.26% 
Table 2. Radiochemical purity of [68Ga]Ga-NOTA-Folate using varying NOTA-Folate precursor 
amounts, calculated by Wizard gamma counter CPS results. *n=3. †n=6.  
 
 
Figure 9. Quality control analysis of concentrated [68Ga]Ga-NOTA-Folate synthesis using 10 nmol of 
NOTA-Folate using iTLC and ARG; (1) [68Ga]Ga-NOTA-Folate end product, (2) 68Ga-Citrate, (3) 













5.3 In Vivo Results.  
 
Upon analysis of the in vivo PET/CT scans, the highest maximum TBR in the aortic arch of 
atherosclerotic mice, measured as SUV, was determined to be 2.6 ± 1.9 (n = 4), which did 
not show a significant difference from the 1.8 ± 0.046 (n = 4) of the healthy control group (P 
= 0.50). Additionally, the %ID/g in the aortic arches of atherosclerotic mice was slightly 
lower than that of the control group at 1.6 ± 0.16 compared to 1.8 ± 0.046, though this 
difference was not significant (P = 0.11).  
 
The atherosclerotic mice showed higher variances among the SUV and %ID/mL in 
comparison to the healthy controls, which could be due to the variations in plaque formation 
among the animals. Upon sacrificing the animals, it was observed that the atherosclerotic 
mice hardly had visible plaque. This could be attributed to various factors, such as a short 
time with the high-fat diet, or the fact that some mice may have eaten more than others. The 
organs with the highest observed accumulation of [68Ga]Ga-NOTA-Folate were the kidneys 
and the bladder, as seen in Figure 10.  
 
      
 
Figure 10.[68Ga]Ga-NOTA-Folate PET/CT images; left represents atherosclerotic mouse, right represents 





          
Figure 11. In vivo coronal segments showing [68Ga]Ga-NOTA-Folate accumulation the (1) kidneys, (2) 
heart, and (3) bladder of mice. 
 
 
Figure 12. Highest maximum TBR in SUV of the aortic arch calculated between atherosclerotic mice and 
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5.4 Ex Vivo Results. 
 
The aortas of the four atherosclerotic mice were analyzed for [68Ga]Ga-NOTA-Folate 
binding in the plaques, adventitia and healthy vessel wall. Upon comparing these tissue 
groups, they were not considered to be significantly different (Pplaque, wall = 0.057, Pplaque, 
adventitia = 0.44, Pwall, adventitia = 0.18). Additionally, the plaque-to-wall binding ratio was 1.44 
 0.17. There was high variations among the plaques, which were all averaged to 40 ± 18 
PSL/mm2 (n=4) and the wall tissues, which was 28 ± 13 PSL/mm2 (n=4).  
 
 
Figure 13. Ex vivo binding of [68Ga]Ga-NOTA-Folate in atherosclerotic mouse aorta. Top represents 








Figure 14. The binding of [68Ga]Ga-NOTA-Folate to plaque, wall and adventitia tissues in atherosclerotic 
mouse aortas ex vivo (mean ± SD, n=4, analyzed using a paired t-test). 
 
The biodistribution of [68Ga]Ga-NOTA-Folate was assessed by ex vivo gamma counting. The 
results showed no significant differences in uptake of [68Ga]Ga-NOTA-Folate between most 
organs of the atherosclerotic mice and the healthy control mice; only the hearts (P = 0.024) 
and stomachs (P = 0.0074) of the atherosclerotic mice showed significantly higher uptake 
when compared to the healthy controls. Additionally, the lymph nodes of the control mice 
had significantly higher uptake than that of the atherosclerotic mice (P = 0.03). The highest 
uptake was seen in the kidneys, with an average of around 25  6.8 %ID/g in atherosclerotic 








Aorta 0.93  0.34 0.48  0.33 P = 0.11  
Muscle 0.19  0.051 0.21  0.023 P = 0.67 
Blood 0.24  0.044 0.22  0.032 P = 0.39 






































Heart 0.24  0.035 0.17  0.031 P = 0.024 
Lungs 0.60  0.29* 0.37  0.099 P = 0.32 
Thymus  0.82  0.86* 0.29  0.12 P = 0.40 
Liver 0.72  0.21 0.50  0.13 P = 0.14 
Spleen 0.12  0.0087 0.12  0.032 P = 0.93 
Pancreas 0.38  0.11 0.30  0.029 P = 0.28 
Kidneys 25  6.8 26  3.4 P = 0.79 
Stomach 0.83  0.15 0.43  0.055 P = 0.0074 
Small 
intestine 
0.51  0.22 0.52  0.20 
P = 0.95 
Large 
intestine 
0.75  0.16 0.51  0.070 
P = 0.054 
Lymph 
nodes 
1.6  0.62 3.3  0.95 
P = 0.030 
WAT 0.26  0.11 0.18  0.025 P = 0.28 
BAT 0.28  0.18 0.18  0.034 P = 0.34 
Bone 0.15  0.060 0.10  0.0094 P = 0.22 
Brain 0.085  0.014 0.072  0.013 P = 0.23 
Femur 0.15  0.057 0.10  0.024 P = 0.23 
Table 3. Ex vivo biodistribution of [68Ga]Ga-NOTA-Folate in mice 120 minutes after injection, with 
results expressed as percent of injected radioactivity dose per gram of tissue (%ID/g) (mean  SD, rounded 
to two significant figures). P-values listed for differences between LDLR-/- ApoB100/100 atherosclerotic 
mice and C57BL/6N control mice analyzed by independent sample t-test (P = 0.05). *n=3. WAT = white 
adipose tissue; BAT = brown adipose tissue. 
 
5.5 Metabolite Analyses. 
 
The in vitro metabolite analysis (n=1) served to determine what tracer standard to use as well 
as the HPLC gradient for the remainder of the metabolite analyses. Following in vivo 
imaging, the plasma of the mice was analyzed for metabolites present. This was analyzed 





results from the HPLC graphs are shown in Figure 16. When compared to the tracer standard, 
one major peak was observed close to the intact tracer.   
 
Following this, a plasma protein binding test was done to determine how much [68Ga]Ga-
NOTA-Folate could have bound to the plasma proteins. This was done by calculating the 
ratio of radioactivity in the supernatant liquid from the plasma to that of the pellet. 
Atherosclerotic mice had an average ratio of 3.8  0.32 (n=4), while the control mice had an 
average of 4.7  0.67 (n=4). There was no statistically significant difference between the two 




Figure 16. Representative radio-HPLC chromatograms of (A) standard [68Ga]Ga-NOTA-Folate in 





















































5.6 In vitro binding in human tissues. 
 
There was significantly higher binding of [68Ga]Ga-NOTA-Folate to atherosclerotic plaque 
in human carotid artery tissues incubated in only [68Ga]Ga-NOTA-Folate than those tissues 
incubated with the added blocker (P  = 0.013, n=8), showing [68Ga]Ga-NOTA-Folate’s 
specificity to bind to FRs.  The same result was observed when comparing the binding to the 
healthy wall tissue, with the binding being higher in the total binding tissues (P = 0.028, 
n=7). Furthermore, the ratio of binding in plaque to binding in healthy wall tissue averaged 
4.7  4.5 in total binding tissues, while that of blocked tissues averaged 1.4  0.13. Even with 




Figure 17. Binding of [68Ga]Ga-NOTA-Folate to plaque in human carotid arteries with and without FR 





































Human Carotid Artery Plaque Binding of [68Ga]Ga-NOTA-
Folate 






Figure 18. Ratio of [68Ga]Ga-NOTA-Folate binding between atherosclerotic plaques and healthy wall 
tissue in human carotid arteries with and without FR blocker (mean ± SD, P = 0.018, n=7, analyzed using 
a paired t-test). 
 
5.7 MI in vitro binding. 
 
 [68Ga]Ga-NOTA-Folate proved to bind specifically to FRs when assessed in post-MI 
inflamed heart tissues with and without folate glucosamine to block the FRs. Binding of 
[68Ga]Ga-NOTA-Folate was expressed in PSL/mm2 values, with an average value of 290 ± 
10 PSL/mm2 in MI scar tissues without blocker. By contrast, the tissues treated with 500 























Plaque-to-Wall Binding of [68Ga]Ga-NOTA-Folate 








Figure 19. Digital autoradiographs showing binding of [68Ga]Ga-NOTA-Folate with (A) no FR blocker 
and (B) with FR blocker in rat hearts 3 days post-MI alongside the same tissues stained with H&E for 
histological reference. 
 
Figure 20. Binding of [68Ga]Ga-NOTA-Folate to MI scar tissue in rat hearts with and without FR blocker 

































MI Scar Tissue Binding of [68Ga]Ga-NOTA-Folate 





When comparing uptake of [68Ga]Ga-NOTA-Folate in MI scar tissue to the remote healthy 
tissue, the ratio of the total binding tissues was significantly higher at 5.2 ± 0.83 PSL/mm2 
than that of the blocked tissues was 1.9 ± 0.52 PSL/mm2 (P = 0.0034, n=4). 
 
 
Figure 21. Ratio of [68Ga]Ga-NOTA-Folate binding between MI scar tissue and remote healthy tissue in 
rat hearts with and without FR blocker (mean ± SD, P = 0.0034, n=4,analyzed using a paired t-test). 
 
Uptake in the remote healthy tissues was also significantly different among the two groups, 
with the total binding tissues averaging 57 ± 30 PSL/mm2 and the blocked tissues averaging 





























MI Scar-to-Healthy Tissue Binding of [68Ga]Ga-NOTA-
Folate 





5 DISCUSSION   
 
While atherosclerosis can be largely prevented by leading a healthy lifestyle and making 
proper dietary choices, many consider this to be too much work and instead adhere to 
Western-type diets. Given that cardiovascular disease is the leading cause of death in 
developed countries affecting millions worldwide, along with the fact that atherosclerosis 
usually goes undetected until MI, stroke, or blood clots occur, there is an urgent need for 
non-invasive diagnosing and disease monitoring. Pre-clinical imaging is a key milestone 
towards achieving this goal, as it is unethical to test newly developed radiotracers directly in 
humans and expose them not only to the radiation, but any potential unknown side effects. 
 
Studies done in vitro help to understand whether a radiotracer will bind to tissues, though 
this cannot account for the numerous biological processes that may affect it in a living 
organism. Pre-clinical imaging gives an essential understanding of how a radiotracer may 
behave once in a biological system, where a multitude of factors can impact its ability to bind 
to the targeted tissues. While mice and humans differ in many ways, the mouse model used 
allowed for plaque to be imaged with some basic understandings of where else a radiotracer 
may accumulate. These understandings are crucial in determining whether a radiotracer is a 
potentially suitable tracer for clinical imaging of atherosclerosis or MI healing. 
 
The novel radiotracer [68Ga]Ga-NOTA-Folate was synthesized successfully and while it did 
not appear to bind to plaques in the aortic arches of atherosclerotic mice in vivo, [68Ga]Ga-
NOTA-Folate did show specific binding to FRs in vitro to plaques in human carotid arteries 
and rat MI scar tissue. While more experiments are needed to confirm the results in vivo, the 
in vitro blocked binding experiments supported the hypothesis that attaching a radionuclide 
to the folate molecule lead to specific binding of the molecule to the FRs present in the 
macrophages. 
 
The radiosynthesis of [68Ga]Ga-NOTA-Folate gave a great result. As the method had been 
done previously, the hypothesis of obtaining a successful end product with high purity, yield 





of elution to measuring the radioactivity of the end product and was conveniently done in a 
radiochemistry lab within the confines of a hot cell.  
 
When optimizing the protocol for synthesizing concentrated [68Ga]Ga-NOTA-Folate, the 
various precursor concentrations used showed that while adding 10 nmol a very high purity 
of 99% can be obtained, only 7 nmol of NOTA-Folate were necessary to achieve the desired 
purity of 95%. By using 7 nmol instead of 10 nmol, 6 L of precursor may be saved per 
synthesis while still ending with a highly pure end product. While the ARG of iTLC is not 
necessary for QC if a gamma counter is available, the results showed clear separation of the 
desired [68Ga]Ga-NOTA-Folate to that of the free 68Ga. This occurred because the free 68Ga 
bound to the citric acid developer, forming 68Ga-Citrate. 68Ga-Citrate is both smaller and 
more polar than [68Ga]Ga-NOTA-Folate, therefore any free 68Ga impurities can be separated 
and detected using iTLC with citric acid as the developer. If iTLC strips are not available, 
another method for analyzing the QC of the end product would be by using HPLC, as was 
done with the in vivo and in vitro experiments. While the QC with HPLC does take 15 
minutes to the 1 minute of gamma counting per full iTLC strip, it serves as a great way to 
verify and visualize the product purity. 
 
While the protocol used for the radiosynthesis of [68Ga]Ga-NOTA-Folate for in vivo and ex 
vivo experiments met each goal, it may be worthwhile to see if there is room for optimization, 
as there was in the concentrated [68Ga]Ga-NOTA-Folate radiosynthesis. Given the results 
from the concentrated radiosynthesis, where high purity of 95% met while using 7 nmol of 
NOTA-Folate precursor, the question is raised as to whether less amounts of NOTA-Folate 
precursor can be used in the first [68Ga]Ga-NOTA-Folate radiosynthesis protocol, as this 
could perhaps be useful for a more efficient use of the precursor. 
 
There was no significant difference in the in vivo uptake of [68Ga]Ga-NOTA-Folate to the 
aortic arch of the atherosclerotic mice when compared to that of the healthy controls. 
Additionally, there was high variation in the uptake among the atherosclerotic mice. While 
it is possible that [68Ga]Ga-NOTA-Folate may not be the most optimal tracer to image 





Folate does bind specifically to FRs led to the expectation and hope that the in vivo results 
would show some significant difference within the groups. Previous experiments aimed at 
assessing a tracer’s ability to target atherosclerotic inflammation have used the same 
experimental mouse model with the same age, gender, and time fed the high-fat diet and, 
while this cannot be validated, the amount of plaque observed during harvesting in the aortic 
arches of the atherosclerotic mice was noticeably less than in previous experiments.  
 
Limitations in the in vivo experiments could be due to the sample size in the being too small. 
As each mouse has its own metabolism that causes plaque development at various rates, 
having more atherosclerotic mice could potentially decrease the variation among results. 
Additionally, as the mice were fed without restrictions, there was no way to know how much 
food each mouse ate. Being that atherosclerosis is a nutrition-related disease, this could cause 
some variation, as some mice may not have eaten as much as others and this could have 
potentially impacted the degree of plaque formation. Another limitation was using male 
mice, therefore it remains unclear if females may metabolize [68Ga]Ga-NOTA-Folate 
differently. Furthermore, while the ROIs were drawn carefully to avoid including outside 
areas, it is also possible that unintentional human error could have caused some unintentional 
variability. Due to these limitations, further experiments should done to try and decrease the 
observed variation before arriving to a definite conclusion. Additionally, the time given the 
high-fat diet could be extended in future experiments to help increase the chances of 
developing more atherosclerotic plaques. 
 
The ex vivo aortas from the imaged atherosclerotic mice showed no significant difference in 
[68Ga]Ga-NOTA-Folate binding among the different tissues present. The plaque-to-wall ratio 
showed that [68Ga]Ga-NOTA-Folate was around 1.4 times more likely to bind to plaques 
than the wall. As the in vivo results showed no difference with high variations in aortic arch 
uptake and there was little observed plaque when harvesting the aorta, further investigation 
should be done before arriving to a definitive conclusion on whether or not [68Ga]Ga-NOTA-






Ex vivo gamma counting showed higher %ID/g in the hearts of atherosclerotic mice than 
those of the healthy control mice. Additionally, the ex vivo gamma counting showed the 
highest uptake of [68Ga]Ga-NOTA-Folate to be in the kidneys with nearly a quarter of the 
%ID/g being found in the kidneys of both experimental groups. This is not surprising, as one 
of the most common limitations with radiotracers is their high uptake in the highly 
metabolically active kidney, contributing to background radiation in the area of interest. 
While they were not available for the ex vivo gamma counting, the bladders showed high 
uptake in the PET/CT images, which was expected as the kidneys excrete toxins via the 
bladder. As the target for imaging was the aortic arch, this high uptake in the kidneys and 
bladder did not contribute greatly to the observed signal of the aortic arch.  
 
Additionally, while it may not have been as high as the kidneys or bladder, the heart had 
higher uptake than most other organs. Among the two groups, uptake of [68Ga]Ga-NOTA-
Folate in the heart was notably higher among the atherosclerotic mice than the controls. The 
exact cause can only be speculated at this point, however one theory may be that as the 
atherosclerotic mice are genetically predisposed to developing more plaque than the healthy 
controls, it is possible that there could have been more plaque among other arteries in the 
heart to which [68Ga]Ga-NOTA-Folate may have bound. Due once more to the high 
variability in the results, more experiments should need to be done to verify whether there is 
truly more accumulation of [68Ga]Ga-NOTA-Folate in the hearts of the atherosclerotic mice 
with some quantifying methods, such as ex vivo ARG, to further support the findings. While 
the uptake of [68Ga]Ga-NOTA-Folate was significantly less than the kidneys and bladder, 
the uptake in the heart could have potentially contributed to some minimal background noise 
in the aortic arch, given their proximity to one another.  
 
Furthermore, a difference in the uptake of [68Ga]Ga-NOTA-Folate in the stomach was 
observed between the two different groups, as the atherosclerotic mice had significantly 
higher uptake than the healthy controls. At this point it is not known why this is, however 
one theory could be that plaque could have built up in the stomach aorta. This theory would 






The uptake of [68Ga]Ga-NOTA-Folate was higher in the control mice in comparison to the 
atherosclerotic mice. It is not currently known why this may have occurred, or if this has 
been seen in previous experiments between atherosclerotic mice and control mice of the same 
strains. This finding raises awareness to retrospectively assess previous experiments and 
quantify any potential differences found in order to determine why this difference in uptake 
may occur.  Additionally, one metabolite was found when analyzing the ex vivo plasma of 
the mice. The identity of this metabolite is not known, nor is its ability to cross or impact 
tissues.  
 
The blocked binding experiments done in vitro demonstrated that [68Ga]Ga-NOTA-Folate 
does indeed bind specifically to FRs, a finding supported in two different tissues and species 
in vitro. Not only was the binding of [68Ga]Ga-NOTA-Folate significantly different among 
the unblocked and blocked plaques, but in the total binding human carotid artery samples, 
the average plaque-to-wall ratio proved that [68Ga]Ga-NOTA-Folate was binding almost five 
times higher to the plaque than the healthy vessel wall. Similarly, the post-MI rat hearts 
showed around five times more binding to the MI scar tissue than that of the remote healthy 
tissue.   
 
Due to the extent of plaque in the human carotid arteries, some of the samples had ruptured 
calcified plaque upon cryosectioning, causing overlap of the tissues. This reduced the number 
of clear ROIs among the tissues. While there were still enough areas available to make 
several ROIs per sample, the damage from the rupture limited the total collection of data. In 
future experiments, as the extent of plaques and calcifications cannot be controlled, perhaps 
some notice of this sensibility causing potential problems may be considered when 
cryosectioning to avoid further damages to the tissues. Additionally, regarding the MI 
healing tissues, only male rat heart sections were used, again echoing the limitation that there 
could be unknown metabolic differences among the genders impacting the healing after MI.  
 
In order to determine whether [68Ga]Ga-NOTA-Folate is suitable for targeting the FRs 
present in active macrophages, high concentrations of folate glucosamine blocker are needed 





that impact [68Ga]Ga-NOTA-Folate binding once in the body. This can mean that while some 
[68Ga]Ga-NOTA-Folate may bind to FRs, it is possible for some other molecule or biological 
process to block the binding of [68Ga]Ga-NOTA-Folate in vivo. To clarify this doubt, 
[68Ga]Ga-NOTA-Folate needs to be studied in vivo and while this has already been 
preliminarily done in atherosclerotic mice, it will need to be done in MI-healing rats to verify 
the specific binding ability to the MI scar tissue.  
 
The next step in assessing the effectiveness of [68Ga]Ga-NOTA-Folate as a radiotracer would 
be to perform more experiments using more animals to decrease variability and feeding the 
high-fat diet for a longer period to give a higher chance for more plaque to develop, and if 
results show specific uptake to atherosclerotic plaques in vivo, [68Ga]Ga-NOTA-Folate 
should be compared with [18F]-FDG to compare their biodistribution. Additionally, in vivo 
experiments should be done to observe whether there is uptake of [68Ga]Ga-NOTA-Folate in 






6 CONCLUSION  
 
Molecular imaging is a fast-growing technique that has the potential to provide a means to 
visualize disease diagnosis, monitoring, and potential treatment options. By studying the 
novel radiotracer [68Ga]Ga-NOTA-Folate pre-clinically, essential information is gained to 
determine whether it is a suitable radiotracer to image inflammation due to atherosclerosis 
and MI healing. 
 
[68Ga]Ga-NOTA-Folate was shown to bind specifically to FRs, indicating that it has potential 
to molecularly image inflammation due to atherosclerotic plaques and healing after MI. More 
PET/CT in vivo imaging experiments should be done to verify its ability to image to 
atherosclerotic plaques due to the high variability observed. [68Ga]Ga-NOTA-Folate uptake 
is high in the kidneys and bladder and one metabolite was observed in the plasma, which 
remains to be identified. As [68Ga]Ga-NOTA-Folate showed significant binding to post-MI 
scar tissue in rats relative to the remote healthy tissue, it seems promising for molecular 
imaging of MI healing and therefore should be assessed in vivo to determine its effectiveness 
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